What is Gallant?
Gallant operates at the intersection of biotechnology and veterinary science, establishing a new category of medicine focused on off-the-shelf stem cell therapies. Unlike traditional veterinary approaches that prioritize symptom management, Gallant targets the underlying biological drivers of disease. The company is led by a team of experts with deep experience in the development, manufacturing, and commercialization of regenerative products. By making these advanced therapies accessible, Gallant is effectively disrupting the pet health market, moving the industry toward a model of restorative health rather than palliative care. Their market position is strengthened by a pipeline designed to address unmet needs in animal health, providing a scalable solution for veterinarians and pet owners alike.
How much funding has Gallant raised?
Gallant has raised a total of $28.2M across 2 funding rounds:
Other Financing Round
$18M
Stock/Share Issuance
$10.2M
Other Financing Round (2025): $18M with participation from Digitalis Ventures and NovaQuest Capital Management
Stock/Share Issuance (2025): $10.2M, investors not publicly disclosed
Key Investors in Gallant
Digitalis Ventures
Digitalis Ventures engineers solutions to unmet needs in health by leveraging deep technical, financial, and domain expertise. The company invests in biotechnology and technology-enabled solutions aimed at improving human and animal health while reducing costs.
NovaQuest Capital Management
NovaQuest Capital Management is a premier biopharma and life sciences investment firm that pioneered a product finance investment solution. They provide at-risk, nondilutive funding that enables partner companies to advance pivotal clinical trials and launch new brands.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Gallant?
With the recent influx of capital, Gallant is poised to accelerate its clinical development pipeline and enhance its manufacturing capabilities. The strategic focus will likely shift toward expanding the commercial footprint of its regenerative therapies, potentially targeting broader therapeutic areas within the veterinary space. As the company matures, the emphasis will remain on clinical validation and the establishment of a sustainable supply chain for its off-the-shelf products. Investors are closely watching how Gallant leverages this financial backing to navigate regulatory pathways and secure market share, ultimately aiming to redefine the standard of care for pets globally. The company's ability to execute on its commercialization roadmap will be the primary indicator of its long-term success in the high-growth animal health sector.
See full Gallant company page
